GLP-1 Pipeline Note: Orforglipron’s Blood-Pressure Trial and CagriSema’s Pending Decision

Research · GLP-1 · Reviewed by Thomas Okafor, Peptide Chemist · Published October 10, 2026

Orforglipron: a trial built around blood pressure

GLP-1 drugs have been linked to lower blood pressure as a secondary finding in many trials. ATTAIN-HYPERTENSION is designed to test it directly. The program runs two identical randomized, placebo-controlled studies in adults with a BMI of 25 or higher and elevated blood pressure. The main outcome is the change in office systolic blood pressure at week 36 [1].

The studies randomized 538 and 546 participants at 100 sites in 10 countries between April 2025 and January 2026. Participants averaged 53.7 years of age, a BMI of 35.6 and a systolic pressure of 144.2 mmHg, and 55.4% were taking blood-pressure medication at screening [1]. The trial is sponsored by Eli Lilly, and several authors are Lilly employees [1]. Orforglipron was approved by FDA for chronic weight management in April 2026; blood pressure is not an approved use.

CagriSema: still waiting

Novo Nordisk submitted CagriSema to FDA for chronic weight management in December 2025 [2]. It combines semaglutide with cagrilintide, a long-acting analog of the hormone amylin. As of this week, no FDA decision has been announced [2].

More on how these compounds are studied: Weight & Metabolism, our semaglutide research guide, and the earlier retatrutide and orforglipron update.

Orforglipron and semaglutide are prescription medicines; CagriSema is investigational. This note reports trial design and regulatory status for education only.